MWA
NRIX icon

Marshall Wace Asia’s Nurix Therapeutics NRIX Stock Holding History

Marshall Wace Asia’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-13,906
Closed -$485K – 178
2020
Q3 		$485K Buy
+13,906
New +$350K 0.01% 119

Other funds holding NRIX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace Asia's NRIX Position: Q4 2020 in Review

Marshall Wace Asia sold out of Nurix Therapeutics (NRIX) in Q4 2020, closing a stake of 13,906 shares — an estimated $485K sold.

Marshall Wace Asia first reported a position in NRIX in Q3 2020 and held it in 1 quarter. The position peaked at $485K in Q3 2020. 68 funds tracked by Wall St. Rank hold NRIX as of Q4 2020.

  • Marshall Wace Asia reported no remaining Nurix Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace Asia sold 13,906 Nurix Therapeutics shares in Q4 2020, an estimated $485K.
  • Marshall Wace Asia first reported a position in Nurix Therapeutics in Q3 2020 and held it in 1 quarter.
  • Marshall Wace Asia's Nurix Therapeutics position peaked at $485K in Q3 2020.
  • 68 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2020.

Based on Marshall Wace Asia's 13F filing for Q4 2020, filed 16 Feb 2021.